ROBERT IMANI: Open Payments
NPI 1639374747 · LANCASTER, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,452 in 57 payments from 11 companies in 2025. Trend: 2023 $1,667 · 2024 $1,544 · 2025 $1,452
Food & beverage: $1,452
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 16 | $475 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $223 |
| Lundbeck LLC | 8 | $192 |
| E.R. Squibb & Sons, L.L.C. | 8 | $167 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $150 |
| ABBVIE INC. | 4 | $100 |
| Alkermes, Inc. | 2 | $53 |
| Axsome Therapeutics, Inc. | 1 | $28 |
| Corium, LLC | 1 | $23 |
| Neos Therapeutics, LP | 1 | $22 |
Products named: REXULTI, TRINTELLIX, COBENFY, CAPLYTA, VRAYLAR, ABILIFY ASIMTUFII, ARISTADA, Auvelity.
Industry payments across CA — which companies pay providers there.
